business / Finance - Earnings
Zi Corporation: Zi Announces 2008 Year-End Financial ResultsCALGARY, ALBERTA (MARKET WIRE) Zi Corporation (TSX: ZIC) (NASDAQ: ZICA) (the "Company" or "Zi"), a provider of intelligent interface solutions, today announced its financial results for the fiscal year ended December 31, 2008.
Market Wire Monday, March 30, 2009Adherex Reports 2008 Fiscal ResultsAnnounces Corporate Restructuring
Market Wire Monday, March 30, 2009MethylGene Reports Fourth Quarter and Full Year 2008 Financial ResultsMONTREAL, QUEBEC--(Marketwire - March 30, 2009) - MethylGene Inc. (TSX:MYG) today announced financial results for the fourth quarter and full year ended December 31, 2008, and provided a summary of the Company's objectives for 2009.
Financial Results Reported in Canadian Dollars
Total revenues, consisting of contract revenues and license fees, for the year ended December 31, 2008 were $29.5 million compared to $15.5 million for the year ended December 31, 2007. The increase in revenues was due primarily to the recording of $14.2 million of license and upfront fees into income from unearned revenue as a result of converting the agreement with Celgene Corporation that was announced in September.
Market Wire Monday, March 30, 2009MethylGene présente ses résultats financiers du quatrième trimestre et de clôture de l'exercice de 2008MONTREAL, QUEBEC--(Marketwire - 30 mars 2009) - MethylGene Inc. (TSX:MYG) a annoncé aujourd'hui ses résultats financiers du quatrième trimestre et de clôture de l'exercice ayant pris fin le 31 décembre 2008. La Société a également présenté un sommaire de ses objectifs pour l'année 2009.
Résultats financiers en dollars canadiens
Les produits d'exploitation, qui comprennent les produits tirés des ententes de recherche et de collaboration en recherche ainsi que les droits de licence et paiements initiaux, s'élevaient à 29,5 M$ au 31 décembre 2008 comparativement à 15,5 M$ à pareille date l'an dernier. Cette augmentation des produits est due principalement à la comptabilisation de 14,2 M$ en droits de licence et paiements initiaux précédemment enregistrés en produits reportés. Cette comptabilisation fait suite à la conversion de notre entente de collaboration avec Celgene Corporation, tel qu'annoncé en septembre.
Market Wire Monday, March 30, 2009MediaNet Group Technologies Announces Financial Results for Fourth Quarter and Full Year of 2008MARGATE, FL--(Marketwire - March 30, 2009) - MediaNet Group Technologies, Inc. (OTCBB: MEDG), operating the largest online mall and affinity program platform
through its BSP Rewards subsidiary, today announced financial results for
the fourth quarter and full year ended December 31, 2008.
For the year ended December 31, 2008, gross revenues were $2.7 million, an
increase of 125% as compared to $1.2 million in 2007. The net loss for the
year was $$837,947, or a loss of $0.04 per basic and diluted share, as
compared to a loss of $977,071, or a loss of $0.08 per basic and diluted
share, for 2007.
Market Wire Monday, March 30, 2009CHDT Corp. Reports Record 134% Annual Sales Increase and 4th Q Revenues of $2,396,000Webcast Scheduled for Monday at 12:00 P.M.
Market Wire Monday, March 30, 2009Juma Technology Announces 2008 Year End EarningsCompany Posts Impressive 70% Year-Over-Year Growth
Market Wire Monday, March 30, 2009Corcept Therapeutics Announces Fourth Quarter and Full Year 2008 Results and Update on Development ProgramsMENLO PARK, CA--(Marketwire - March 30, 2009) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the development of drugs for the
treatment of severe psychiatric and metabolic disorders, today updated its
corporate progress, reported financial results for the fourth quarter and
the full year ended December 31, 2008, and outlined its corporate outlook
for 2009.
"The past year has been one of significant progress across all of our
development programs. We initiated Phase 3 trials of CORLUX® in
psychotic depression and in Cushing's Syndrome -- indications for which
there is significant unmet medical need. We also continued to advance our
next-generation selective GR-II antagonists, generating important proof of
concept data supporting their use for the mitigation of antipsychotic
induced weight gain. We now have a large and growing body of data
supporting the broad potential
Market Wire Monday, March 30, 2009MDN Posts Record 2008 Net Earnings of $22.1 Million or $0.24 per ShareMONTREAL, QUEBEC--(Marketwire - March 30, 2009) - MDN Inc. (TSX:MDN) ("MDN") released today its audited financial statements for the year ended December 31, 2008. Management's analysis of the financial situation as well as the audited statements are available on the Company's website (www.mdn-mines.com) and on SEDAR (www.sedar.com).
KEY RESULTS FROM FISCAL 2008
- Revenues climbed to $27,256,716, up from $1,570,637 for the same
period in 2007.
- Net earnings were $22,127,336 or $0.241 per share, compared to a net loss of $11,405,625 or $0.138 per share over the same period in 2007.
Market Wire Monday, March 30, 2009MDN dégage un bénéfice net record de 22,1 M$ ou 0,24 $ par action en 2008MONTREAL, QUEBEC--(Marketwire - 30 mars 2009) - MDN inc. (TSX:MDN) ("MDN") a déposé aujourd'hui ses états financiers vérifiés pour l'exercice financier se terminant le 31 décembre 2008. L'analyse de la situation financière par la direction et les états financiers vérifiés sont disponibles sur le site web de la Société (www.mdn-mines.com) et sur SEDAR (www.sedar.com).
FAITS SAILLANTS DE L'EXERCICE FINANCIER 2008
- Revenus nets de 27 256 716 $ comparativement à 1 570 637 $ au cours de la même période en 2007.
Market Wire Monday, March 30, 2009 1 2 3
Archived finance - earnings news stories.
Available news archives.